Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“Neoadjuvant T-DXd may become a new available tool for the curative treatment of HER2+ breast cancer.
How would you treat a patient with stage II (T2N1), ER+/HER2+ breast cancer, who has received 4 cycles of THP with apparent clinical and radiologic resolution of her tumor?”
Proceed to the pool attached to the post.
More posts featuring Paolo Tarantino on OncoDaily.